Drug Type Small molecule drug |
Synonyms BEBT 607, BEBT-607, BEBT607 |
Target |
Action inhibitors |
Mechanism KRAS G12C inhibitors(GTPase KRas G12C inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
KRAS G12C mutation Solid Tumors | Phase 1 | China | 04 Sep 2023 | |
KRAS G12C mutant Colorectal Cancer | Phase 1 | China | - | |
KRAS G12C mutant Non-small Cell Lung Cancer | Phase 1 | China | - | |
KRAS p.G12C mutant pancreatic cancer | Phase 1 | China | - |